Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination
Introduction: The combination of atezolizumab, an immune checkpoint inhibitor (ICI), and bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, is the first choice for systemic therapy in hepatocellular carcinoma. Immune-related cardiovascular toxicity—myocarditis and pericarditis—are k...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Frontiers Media S.A.
2023-08-01
|
| Schriftenreihe: | Frontiers in Drug Safety and Regulation |
| Schlagworte: | |
| Online-Zugang: | https://www.frontiersin.org/articles/10.3389/fdsfr.2023.1213771/full |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|